Bronchiectasis has progressed from a historically neglected condition to a focal point in translational respiratory medicine. The field has seen notable developments, including regulatory approval of the first bronchiectasis therapy in the United States and Europe in 2025. This milestone is complemented by the emergence of evidence-based guidelines and a sustained rise in published research, alongside the initiation of several new large clinical trials. The growing activity has elevated bronchiectasis to a prominent position within the respiratory science community. The Lancet Respiratory Medicine Commission presents a strategic, potentially transformative view for the field. While the specific recommendations are not detailed here, the piece signals an intent to recalibrate priorities, methodologies, and collaboration across investigators, clinicians, and stakeholders. It implies a broad, systems-level reorientation that could influence future research directions, clinical practice, and policy. Uncertainty in this summary arises from the absence of explicit content describing the Commission’s proposed mechanisms, concrete actions, or assessed risks and benefits. The cited progress and the notion of a “shake-up” suggest substantial but unspecified changes.
A historically neglected disease, bronchiectasis now represents an exemplar of progress through modern translational medicine.1,2 2025 saw the first approved therapy for bronchiectasis by regulators in the USA and Europe,3 new evidence-based guidelines,4 a record number of publications,1 the initiation of several new large clinical trials, and its highest ever profile within the respiratory community.5 Against this backdrop, it might seem counterintuitive to propose the biggest ever “shake-up” of the field through a Lancet Respiratory Medicine Commission.